A review of in vitro and early preclinical findings on Epithalon’s proposed effects on hTERT expression, telomerase activity, and telomere length in aging cell models, with attention to translational limitations.

An exploration of Semax mechanisms involving BDNF-TrkB signaling, downstream MAPK/ERK and PI3K/Akt cascades, and region-specific neurotrophin expression patterns in preclinical ischemia research.

This article reviews preclinical research on Noopept’s proposed neurotrophin signaling mechanisms, including the role of its metabolite cycloprolylglycine and reported effects on NGF/BDNF expression and AMPA receptor modulation in rodent models.

An in-depth look at Selank’s preclinical pharmacology across serotonin, GABA, and neurotrophin pathways, with attention to study limitations and the translational evidence gap.

A research-context examination of Noopept’s documented effects on NGF and BDNF mRNA expression in hippocampal tissue, distinguishing acute vs. repeated exposure findings and identifying key translational limitations.

An overview of preclinical research on Epithalon’s influence on AANAT enzyme expression, pCREB transcriptional activity, and melatonin biosynthesis in pinealocyte models.

Preclinical research overview of Selank’s GABA-A allosteric modulation, enkephalin degradation enzyme inhibition, and serotonin turnover in anxiety and stress rodent models.

An analysis of Semax preclinical research involving striatal dopamine and serotonin metabolite modulation, BDNF/TrkB neuroprotective pathways, and divergence from classical ACTH melanocortin receptor activity in rodent model studies.

An analysis of Epithalon (AEDG tetrapeptide) in preclinical research contexts, covering telomerase activation via TERT upregulation, pineal gland signaling, and neuronal aging model findings.

A preclinical review of Noopept’s region-specific neurotrophin expression patterns, highlighting hippocampal NGF and BDNF mRNA dynamics and the signaling context relevant to memory consolidation research.